Plain-English translation of NCT06671587 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether iGlarLixi, a new insulin medication that combines two active ingredients, works better than standard insulin (Gla-100) at keeping blood sugar in a healthy range throughout the day. Researchers will track your blood sugar continuously using a small wearable device and measure how much time your glucose stays within the target range over 20 weeks.
Many people with type 2 diabetes find that taking oral pills alone doesn't control their blood sugar well enough, and they need to start insulin. This study wants to see if this newer insulin combination medication can better help people achieve their blood sugar goals compared to the standard insulin treatment currently used.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic about 9 times over 5-6 months, plus have 5 phone check-ins. Starting at week 1, you will inject the medication once daily and wear a continuous glucose monitor that tracks your blood sugar automatically. Your dose will be adjusted at clinic visits based on your fasting blood sugar readings until you reach your target range. You will also check your blood sugar at home using a provided device and keep track of your readings.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
China